DALLAS, June 7, 2017 /PRNewswire/ -- Nexeon MedSystems, Inc. ("Nexeon" or "Company"), an SEC full reporting
Chairman and CEO Will Rosellini said: "We are pleased to have aligned our capital strategy in a way that benefits our earliest shareholders, opens the investment opportunity to a more diversified investor pool, and allows for a more efficient pricing structure to existing and new shareholders as we prepare to begin trading on the OTC:QX in the near future."
Nexeon will not receive any proceeds from the sale of the common shares by the selling security holders. Upon the cash exercise of the warrants, Nexeon will receive the exercise price of the warrants.
Rosellini went on to note that he is not listed in the registration statement as a security holder that is participating in the resale of his Common Shares. He has indicated that he has no plans to sell any of his shares in the foreseeable future.
About Nexeon MedSystems, Inc: Nexeon Medsystems, Inc. is a global medical device company focused on providing innovative neurostimulation products that improve the quality-of-life of patients suffering from debilitating neurological diseases. Nexeon has developed and commercialized a neurostimulation system that can be utilized to treat a variety of neurological diseases.
Forward-Looking and Cautionary Statements: Statements in this press release that are not strictly historical may be "forward-looking" statements, which involve risks and uncertainties, and Nexeon undertakes no obligation to update any such statements to reflect later developments. These risks and uncertainties include Nexeon's ability to successfully complete on the terms and conditions contemplated, and the financial impact of, its strategic portfolio repositioning actions, as well as economic and currency conditions, market demand, pricing, protection of intellectual property, and competitive and technological factors, among others, as set forth in Nexeon's subsequent reports filed with the SEC.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nexeon-s-1-registration-statement-declared-effective-by-sec-300470789.html
SOURCE Nexeon Medsystems, Inc.
Subscribe to our Free Newsletters!
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...
Dizziness is a feeling of being faint or unsteady whereas Vertigo is a feeling that you or your ...View All